Bone complications in patients with multiple myeloma in five European countries: a retrospective patient chart review

BMC Cancer

Michele Intorcia¹  Christina Giannopoulou¹  Daniela Niepel²  María-Victoria Mateos³  Niranchana Koneswaran⁴  Leah Fink⁴  Michele Cavo⁵ 

[1] Amgen (Europe) GmbH;Amgen (Global Medical Affairs) GmbH;Haematology Service, University Hospital Salamanca/IBSAL;Kantar Health;Seragnoli Institute of Haematology and Medical Oncology, Bologna University School of Medicine;

关键词: Chart review;    Bisphosphonates;    Bone complications;    Denosumab;    Europe;    EU5;   

DOI  :  10.1186/s12885-020-6596-y

来源: DOAJ

【 摘 要 】

Abstract Background Bone complications (pathologic fracture, spinal cord compression, surgery to bone and radiation to bone) are a common problem in patients with multiple myeloma (MM). We set out to provide insights into the real-world burden of bone complications in patients with newly diagnosed MM (NDMM). Methods We conducted a retrospective review of medical charts of patients with NDMM whose disease had progressed following first-line treatment in the 3 months before data collection in 2016 in five European countries (France, Germany, Italy, Spain and the United Kingdom). Results The aggregated study population included 813 patients. Bone pain commonly led to MM diagnosis (63%) and 74% of all patients had two or more bone lesions at initiation of first-line treatment. Furthermore, 26% of patients experienced a new bone complication between MM diagnosis and disease progression following first-line treatment, despite 75% of individuals receiving bisphosphonates. Most bone complications (52%) occurred in the period before initiation of first-line treatment (mean duration: 2.3 months) and more than half of patients (56%) who experienced a new bone complication were hospitalised. Analgesics were used more frequently in patients with bone complications than in those without them (76% vs 50%, respectively). Furthermore, 51% of patients had renal impairment by the time first-line treatment was started. Overall, 25% of patients did not receive bisphosphonates for prevention of bone complications and one in four of those with renal impairment at initiation of first-line treatment did not receive bisphosphonates. Conclusions Bone complications are common in patients with NDMM. They are frequently associated with hospitalization and analgesic use. Data from this study, conducted in the era of novel anti-myeloma therapies and before the approval of denosumab for use in patients with MM, suggest that although most patients (75%) received bisphosphonates, use of anti-resorptive therapy for prevention of bone complications may be suboptimal in patients with NDMM, irrespective of renal function.

【 授权许可】

Unknown